Ionis Pharmaceuticals, Inc. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Ionis Pharmaceuticals, Inc. (IONS) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$84.80 million for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2012-02-29
- Ionis Pharmaceuticals, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2010-12-31 was -$13.99M.
- Ionis Pharmaceuticals, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2010-09-30 was -$12.45M.
- Ionis Pharmaceuticals, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2010-06-30 was -$25.15M.
- Ionis Pharmaceuticals, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2009-12-31 was -$16.83M.
- Ionis Pharmaceuticals, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2011 was -$84.80M.
- Ionis Pharmaceuticals, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2010 was -$61.25M.
- Ionis Pharmaceuticals, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2009 was -$34.96M.
- Ionis Pharmaceuticals, Inc. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2008 was -$14.52M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2011-12-31 | -$84.80M 10-K · filed 2012-02-29 | |||
| 2010-12-31 | -$13.99M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | -$26.44M derived: sum of 2 quarters · filed 2012-02-29 | -$51.59M derived: sum of 3 quarters · filed 2012-02-29 | -$61.25M 10-K · filed 2012-02-29 |
| 2010-09-30 | -$12.45M 10-Q · filed 2010-11-05 | -$37.61M derived: sum of 2 quarters · filed 2010-11-05 | -$47.27M 10-Q · filed 2010-11-05 | |
| 2010-06-30 | -$25.15M 10-Q · filed 2010-08-09 | -$34.81M 10-Q · filed 2010-08-09 | ||
| 2009-12-31 | -$16.83M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | -$29.58M derived: sum of 2 quarters · filed 2012-02-29 | -$33.27M derived: sum of 3 quarters · filed 2012-02-29 | -$34.96M 10-K · filed 2012-02-29 |
| 2009-09-30 | -$12.75M 10-Q · filed 2010-11-05 | -$16.43M derived: sum of 2 quarters · filed 2010-11-05 | -$18.12M 10-Q · filed 2010-11-05 | |
| 2009-06-30 | -$3.68M 10-Q · filed 2010-08-09 | -$5.37M 10-Q · filed 2010-08-09 | ||
| 2008-12-31 | -$14.52M 10-K · filed 2011-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |